J&J Terminates Icagen Deal For Senicapoc
This article was originally published in The Pink Sheet Daily
Executive Summary
Icagen says it will decide whether to continue development of the drug in sickle cell anemia by this fall.
You may also be interested in...
Sparks Fly: Pfizer and Icagen Unite To Study Sodium Ion Channels For Pain
Targets in the deal are important in generation of electrical signals in nerve fibers that mediate the initiation and sensation of pain, firms say.
Sparks Fly: Pfizer and Icagen Unite To Study Sodium Ion Channels For Pain
Targets in the deal are important in generation of electrical signals in nerve fibers that mediate the initiation and sensation of pain, firms say.
Icagen/J&J Terminate Phase III Sickle Cell Trial
Data monitoring committee advises low probability of achieving crisis reduction endpoint.